Qiagen (NYSE:QGEN) Shares Sold by Amalgamated Bank

Amalgamated Bank decreased its position in Qiagen (NYSE:QGEN) by 4.0% in the 3rd quarter, Holdings Channel reports. The fund owned 11,633 shares of the company’s stock after selling 491 shares during the period. Amalgamated Bank’s holdings in Qiagen were worth $530,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. US Bancorp DE lifted its stake in Qiagen by 0.8% during the third quarter. US Bancorp DE now owns 69,122 shares of the company’s stock worth $3,150,000 after purchasing an additional 580 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in Qiagen by 39.9% during the third quarter. Assenagon Asset Management S.A. now owns 12,184 shares of the company’s stock worth $550,000 after purchasing an additional 3,474 shares during the last quarter. Private Advisor Group LLC lifted its stake in Qiagen by 8.0% during the third quarter. Private Advisor Group LLC now owns 6,251 shares of the company’s stock worth $285,000 after purchasing an additional 461 shares during the last quarter. Signaturefd LLC lifted its stake in Qiagen by 9.7% during the third quarter. Signaturefd LLC now owns 8,038 shares of the company’s stock worth $366,000 after purchasing an additional 714 shares during the last quarter. Finally, Sequoia Financial Advisors LLC lifted its stake in Qiagen by 2.8% in the third quarter. Sequoia Financial Advisors LLC now owns 18,618 shares of the company’s stock valued at $848,000 after buying an additional 511 shares during the last quarter. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on QGEN. HSBC cut Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price on the stock. in a research note on Thursday, October 17th. Robert W. Baird raised their target price on Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Finally, Hsbc Global Res upgraded Qiagen to a “hold” rating in a research note on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $50.88.

Qiagen Stock Performance

QGEN opened at $41.27 on Friday. The stock has a market cap of $9.42 billion, a price-to-earnings ratio of 105.82, a PEG ratio of 3.24 and a beta of 0.41. The company has a quick ratio of 1.46, a current ratio of 2.17 and a debt-to-equity ratio of 0.39. Qiagen has a 12-month low of $39.03 and a 12-month high of $47.44. The business has a 50 day moving average of $43.85 and a 200-day moving average of $43.76.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.